Real-time PCR-based analysis of BRAF V600E mutation in low and intermediate grade lymphomas confirms frequent occurrence in hairy cell leukaemia by Ewalt, Mark et al.
Hematological Oncology
Hematol Oncol 2012; 30: 190–193
Published online 22 December 2011 in Wiley Online Library
(wileyonlinelibrary.com) DOI: 10.1002/hon.1023Original Research Article
Real-time PCR-based analysis of BRAF V600E mutation in
low and intermediate grade lymphomas confirms frequent
occurrence in hairy cell leukaemia
Mark Ewalt1†, Subhadra Nandula1†, Adrienne Phillips2, Bachir Alobeid1, Vundavalli V. Murty1,
Mahesh M. Mansukhani1* and Govind Bhagat1*
1Department of Pathology and Cell Biology, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY, USA
2Department of Medicine, Division of Hematology and Oncology, Columbia University Medical Center and New York Presbyterian Hospital, New
York, NY, USA*Correspondence to:
Govind Bhagat and Mahesh M.
Mansukhani, Department of
Pathology and Cell Biology,
Columbia University Medical
Center and New York Presbyterian
Hospital, 630 West 168th Street,
VC 14–228, New York, NY, USA.
E-mail: gb96@columbia.edu;
E-mail: mm322@columbia.edu
†These authors contributed equally
to this work.
Received 5 October 2011
Revised 4 November 2011
Accepted 7 November 2011Copyright © 2011 John Wiley & SonAbstract
Hairy cell leukaemia (HCL) is a rare type of B-cell non-Hodgkin lymphoma (B-NHL),
which is not known to be associated with any characteristic recurrent karyotypic
abnormality. A recent study that used massively parallel whole exome sequencing identified
an activating V600E mutation in BRAF, which appeared specific for HCL. Here, we confirm
the specificity of BRAF V600E for HCL among low and intermediate grade B-NHL and
describe a real-time polymerase chain reaction method for detecting this mutation in
cases with low tumour burden. The V600E mutation does not appear to be associated
with microsatellite instability, unlike the case in colorectal cancer. Thus, in conjunction
with prior data, our results suggest incorporation of BRAF V600E mutation analysis in
the diagnostic workup of HCL cases. Additionally, targeting the Ras-Raf-Mek-Erk-Map
kinase pathway should be investigated as a potential therapeutic strategy for patients
with this disease. Copyright © 2011 John Wiley & Sons, Ltd.Keywords: BRAF V600E; hairy cell leukaemia; non-Hodgkin lymphomaIntroduction
Recent advances in technology, especially high resolution
whole genome analyses, have yielded clues to the molecu-
lar pathogenesis of a variety of neoplasms that lacked recur-
rent cytogenetic alterations, as ascertained by conventional
methods [1]. In an early study analysing cancer genomes
for recurrent mutations, Davies et al. discovered activating
mutations of BRAF in exons 11 and 15, most frequently in
melanoma (up to 66% of cases harboured such a mutation),
with the V600E (c.1799 T>A) mutation being the most
common [2]. Until recently, data regarding the presence
and frequency of BRAF mutations in lymphomas were
limited. Lee et al. identified somatic BRAF mutations in
4 of 164 (2.4%) non-Hodgkin lymphomas (NHL), all
representing diffuse large B-cell lymphomas. The V600E
mutation was not identified in this series [3]. BRAF
mutations were recently detected in 4% of multiple
myeloma by a multi-institutional consortium on performing
whole genome and exome analyses of 38 samples and
screening an additional 161 cases, with four (2%) cases
harbouring theV600E mutation [4]. More recently, Tiacci
et al. also identified a V600E BRAF mutation in an index
case of hairy cell leukaemia (HCL) with the use of
massively parallel whole exome sequencing, and the
authors further showed that this mutation was present in
all 47 additional HCL analysed with Sanger sequencing [1].
These authors suggested that the BRAF V600E mutations, Ltd.may account for the activated phenotype of HCL, as a BRAF
inhibitor could inhibit downstream ERK andMEK phosphor-
ylation in vitro, and that targeting this pathway may be of
therapeutic value [1]. Recently, Boyd et al. verified the pres-
ence of the V600Emutation in HCL patients with the use of a
high resolution melting analysis assay [5].
In this study, we sought to investigate the presence of
BRAF V600E mutations in a large panel of low and inter-
mediate grade B-cell non-Hodgkin lymphoma (B-NHL)
comprising different subtypes, and to assess any association
of this mutation with microsatellite instability (MSI). We
used a real-time polymerase chain reaction (PCR)-based
assay to detect the mutation in unpurified peripheral blood,
bone marrow and tissue samples, obtained fresh and also af-
ter fixative treatment. Limiting dilution analysis demon-
strated utility of this assay in detecting V600E mutation in
samples with a low tumour burden.Materials and methods
Case selection
Our departmental archive was searched for cases of low
and intermediate grade B-NHL diagnosed at our institution
between 1 January 2000 and 15 August 2011. The selected
B-NHL (n = 102) were classified according to the 2008
World Health Organization Classification [6], as HCL
(n=12 from eight patients), chronic lymphocytic leukaemia/
191BRAF V600E mutations in B-cell lymphomassmall lymphocytic lymphoma (n=20), mantle cell lymphoma
(n=19), marginal zone lymphoma (MZL, n = 24); repre-
senting 18 extranodal MZL, stomach (n = 6), lung
(n=4), eye/ocular adnexa (n=4), and thymus, kidney, ileum
and rectum (n=1 each); four nodal MZL; and two splenic
MZL, follicular lymphoma (n=20) and lymphoplasmacytic
lymphoma (n=7). DNA was extracted with the use of
DNAzolW (Invitrogen, Carlsbad, CA) for samples fixed with
Carnoy’s solution as previously described [7], or with the
use of the QIAampW tissue and blood kits (Qiagen, Valencia,
CA) for fresh and formalin-fixed samples, as per manufac-
turer’s instructions. Tumour percentagewas evaluated through
flow cytometry in nine HCL samples, and immunohistochem-
istry for CD20, TRAP and DBA-44 in three HCL samples.
This study was approved by our institutional review board.
Detection of BRAF V600E mutation
Presence of BRAF V600E mutation was determined with
the use of a real-time PCR assay and allele-specific hydro-
lysis (‘Taqman’) probes. TaqmanW Universal PCR Master
Mix (Applied Biosystems, Carlsbad, CA) was used to
amplify a 136 bp DNA fragment. Wild type and mutant
alleles were distinguished with the use of competing
TaqmanW probes. The primers and probes used for PCR
amplification (B-raf-51F and B-raf-176R) have been
previously described [8]. Briefly, the PCR assay was per-
formed on an ABI 7500 (Applied Biosystems, Carlsbad,
CA) standard real-time ddCT relative quantification
plate with the use of the BRAF-mutant—FAM-
TAGCTACAGAGAAATC and BRAF-wild type—VIC-
CTAGCTACAGTGAAATC \probes. A sample was
considered to harbour the BRAF V600E mutation if the
difference in the threshold cycle (dCt) between amplifica-
tion of mutant and wild type sequence was less than or
equal to eight cycles. (Figure 1). The detection limit (per-
cent tumour cells) was determined by diluting DNA,
which was extracted from a fresh HCL sample with
known neoplastic cell percentage (Patient 6, Table 1), with
normal high molecular weight DNA extracted using the
same method. The mutant allele was also detected through
the dilution of the A2058 cell line DNA in normal DNA.A
Wild type
Mutant
Figure 1. Representative results from the real-time PCR assay for d
marginal zone lymphoma, stomach). (B) Positive case (hairy cell leuk
(VIC), and blue curves represent mutant (c1799T> A pV600E) prob
Copyright © 2011 John Wiley & Sons, Ltd.Analysis for microsatellite instability
Microsatellite instability analysis was performed using
the MSI Analysis System, version 1.2 (Promega Corp,
Madison, WI). This assay entails a multiplex reaction of
five quasi-monomorphic mononucleotide repeat markers
(BAT-25, BAT-26, MONO-27, NR-21 and NR-24) and
also entails two highly polymorphic pentanucleotide
markers (Penta C and Penta D) as sample identifiers. After
PCR amplification, samples were analyzed with ABI 3100
Avant™ (Applied Biosystems, Carlsbad, CA) for altered
alleles. In the absence of normal DNA for comparison, a
sample was considered microsatellite-high (MSI-H) if
greater than two markers showed an altered pattern, inde-
terminate if only two showed an alteration and microsatel-
lite stable (MSS) if no marker showed an altered allele (or
MSS with an allele polymorphism if only one marker
showed an altered allele).Results
The clinical characteristics of hairy cell leukaemia cases are
presented in Table 1. Of note, one case (Patient 8) had an
atypical immunophenotype, as detected by flow cytometry
(CD103 negative), but it expressed CD25 and TRAP by im-
munohistochemistry. Another case (Patient 7) presented
with axillary lymphadenopathy without significant spleno-
megaly. We purified DNA from tumour samples and used
the real-time PCR assay to assess for the presence of BRAF
V600E mutation (Table 2). The BRAF V600E mutation
was detected in all cases where the tumour percentage in
the analysed tissue exceeded 5%. In two patients (Patients
2 and 5), no mutation was detected in the samples with
low tumour burden (≤5% tumour cells) but was detected
in additional samples containing a higher frequency of neo-
plastic cells. We, thus, confirm the results of Tiacci et al. in-
dicating a high prevalence of BRAF V600E mutation in
HCL. The detection of the V600E mutation in an atypical
CD103 negative HCL case and a case with an atypical clin-
ical presentation highlights the utility of this analysis to di-
agnose challenging cases of HCL.B
Wild type
Mutant
etection of BRAF V600E mutation. (A) Negative case (extranodal
aemia, Patient 6, spleen). Black curves represent wild type probes
es (FAM)
Hematol Oncol 2012; 30: 190–193
DOI: 10.1002/hon
Table 2. BRAF V600E mutation detection in HCL samples
Patient Tissue type Tumour% WT Ct Mutant Ct dCt BRAF V600E
1 Bone marrow 3.7%* 32.817 35.478 2.661 Mutant
2 lung 5%** 29.932 39.83 9.898 Wild type
Bone marrow 13.4%* 29.273 31.6 2.327 Mutant
Lymph node 80%** 30.045 32.145 2.1 Mutant
3 Bone marrow 35.3%* 31.135 33.78 2.645 Mutant
4 Bone marrow 0.6%* 34.142 45 10.858 Wild type
5 Peripheral blood 3.1%* 29.757 37.78 8.023 Wild type
Bone marrow 23.0%* 31.089 33.531 2.442 Mutant
6 Peripheral blood 42.9%* 28.341 30.298 1.957 Mutant
Spleen 78.4%* 24.81 24.968 0.158 Mutant
7 Lymph node 70%** 27.819 31.116 3.297 Mutant
8 Bone marrow 5.7%* 30.337 36.597 6.26 Mutant
dCt: difference in the threshold cycle; WT: wildtype; Ct: threshold cycle.
*Tumour percentage based on flow cytometry.
**Tumour percentage assessed by immunohistochemical staining for CD20, DBA-44 and TRAP.
Table 1. Clinical characteristics of HCL patients
Patient Age at diagnosis Sex Presentation Treatment†
1 58 M Pancytopenia Rituximab
2 69 M Pancytopenia Cladribine
3 46 M Pancytopenia Unknown
4 41 M Pancytopenia Unknown
5 53 M Pancytopenia Cladribine, Rituximab/Cladribine, Cladribine
6 43 F Pancytopenia, splenomegaly Cladribine, Pentostatin (2 rounds),
Rituximab/Pentostatin, Splenectomy
7 61 M Pancytopenia,
lymphadenopathy, weakness
None
8* 30 M Pancytopenia None
†Sequential treatment regimens.
*This case represents an HCL with an atypical phenotype.
192 M Ewalt et al.To further evaluate the sensitivity of our real-time assay,
we performed limiting dilution analysis with the use of the
spleen sample from Patient 6 (Table 2), diluting the
extracted DNA with wild type genomic DNA. We were
able to detect the BRAF V600E mutation at a dilution ratio
of 1:8 (9.8% tumour cells) (Table 3). We were similarly
able to detect the mutant allele in a 10% dilution of the
A2058 cell line DNA in normal DNA, or approximately
5% mutant allele (data not shown). The absolute limit of
detection may be improved with further refinement of
this assay. At present, it provides sensitivity within the
range of 5% and 10% tumour cells, demonstrating the valueTable 3. Limiting dilution analysis to determine mutation
detection sensitivity of the real-time PCR assay
Dilution Tumour% dCt BRAF V600E
1:1 78.4% 0.3 Detected
1:2 39.2% 0.6 Detected
1:4 19.6% 3.1 Detected
1:8 9.8% 5.2 Detected
1:16 4.9% 11.4 Not Detected
1:32 2.5% 13.1 Not Detected
dCt: difference in the threshold cycle.
Tumour% based on flow cytometry.
DNA was extracted from fresh splenic tissue (Patient 6).
Copyright © 2011 John Wiley & Sons, Ltd.of real-time PCR in screening for the BRAF V600E muta-
tion in HCL samples where the neoplastic cellular yield is
often limited because of underlying myelofibrosis.
We next sought to evaluate the specificity of the BRAF
V600E mutation for HCL among low and intermediate
B-NHL by evaluating for the presence of this mutation in
90 additional cases of B-NHL with a >20% tumour
burden. We found that none of these additional cases
harboured the BRAF V600E mutation, supporting the
notion that this alteration is specific to HCL (Table 4).
Previous studies of mutations in the Ras-Raf-Mek-Erk-Map
kinase pathway have found an association between BRAF
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193BRAF V600E mutations in B-cell lymphomasBRAF V600E mutations were also described in three of
nine (33%) immunodeficiency-related NHL displaying
MSI, which consisted of EBV+ diffuse large B-cell lym-
phomas, including a primary CNS lymphoma, and an
EBV-T-cell post-transplant lymphoproliferative disorder
[10]. We, thus, investigated whether HCL with BRAF
mutations showed evidence of MSI. Interestingly, all
cases exhibited an MSS phenotype with using a sensitive
assay.Discussion
Hairy cell leukaemia is a rare and enigmatic B-NHL that
predominantly involves the bone marrow and spleen. It
lacks characteristic chromosome abnormalities, and its
aetiology has remained elusive ever since its recognition
as a unique subtype of B-NHL [6,11–13]. The neoplastic
small B-cells exhibit ‘hairy’ cytoplasmic projections and
have an activated phenotype, which may explain their
response to purine analogues and interferon therapy.
The ubiquitous occurrence and high specificity of the
BRAF V600E mutation for HCL among B-NHL, as
recently described [1,5], was confirmed in our series of HCL
with the use of a real-time PCR assay. We were able to iden-
tify this mutation in seven of eight (87.5%) patients. We also
have shown that this mutation was not present in 90 additional
samples comprising a variety of low and intermediate grade
B-NHL, further supporting the notion that the BRAF V600E
mutation is a specific genetic alteration in HCL.
Tiacci et al. reported a sensitivity of approximately 30%
tumour cells for the detection of BRAF V600E using
Sanger sequencing [1]. Here, we describe a method that
detects this mutation in cases with a lower tumour burden
by using either fresh or fixed archival tissue, within range
of the method by Boyd et al. [5].
Taken together, our data and other published data
suggest that the BRAF V600E mutation is specific for
HCL among low to intermediate grade B-NHL. Prior
studies have shown that the BRAF V600E mutation leads
to activation of the MAP kinase pathway via sequential
phosphorylation of downstream signalling mediators.
BRAF inhibition abrogates this activation, suggesting a
potential role for BRAF inhibition in the treatment of
refractory/resistant HCL [1,2]. Further studies will help
elucidate the exact pathogenic effects of this mutation.
Given the high specificity of this mutation, it might also
become an integral part of disease classification in the
future. Our study did not include cases of HCL variants
and only two cases of splenic MZL were evaluated, which
were both negative. Analysis of additional such cases needs
to be undertaken in order to confirm specificity of this mu-
tation for HCL among low and intermediate grade B-NHL.Conclusion
In summary, we describe a sensitive method to specifically
detect the BRAF V600E mutation in patient samples downCopyright © 2011 John Wiley & Sons, Ltd.to a concentration of 5% to 10% tumour cells. The current
assay demonstrates an improved detection limit compared
to direct Sanger sequencing and could thus be useful for di-
agnosis and therapy selection. Disease monitoring follow-
ing treatment, however, may require an allele-specific
PCR approach, or other sensitive methods that can detect
low level mutant alleles.Authorship contributions
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